A total of 22 patients have been recruited to the study, which has been designed in consultation with the FDA, (the US Food and Drug Administration). The results of the study will be reported within a few months.

22 patients have been included in the clinical study, which started during the autumn of 2008. Lungs from further patients have been evaluated using the STEEN Solution™ method, but have been assessed as not being sufficiently good to be transplanted.

The STEEN Solution™ method considerably increases the number of potential organs that can be transplanted. Today less than 20 percent of the lungs donated in the USA are transplanted, due to uncertainty about the functioning of the organ. In the long term the STEEN Solution™ method can lead to five to ten times more lung transplantations being performed, as the demand for donated organs using today's methods considerably exceeds the supply.

STEEN Solution™ is approved for sales in Europe, i.e. it is CE marked. The recently completed clinical study in Canada will be part of an application for sales approval in the USA and Canada.

February 8, 2010
Gothenburg

Magnus Nilsson
CEO

Queries should be addressed to:
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13